Session Abstract – PMWC 2022 Silicon Valley


The value of data in healthcare is undeniable and realized when raw information is successfully converted into knowledge that changes clinical practice. To drive value improvements and ensure that the right patient receives the right care requires the right data in combination with the right data analytics. This session will cover various aspects and challenges of data science in hospitals and health systems that drive healthcare with better outcomes.

Sessions:

  • Data Sharing Application: Needs, Advancements, and Challenges
    - Russ Cucina, UCSF
  • Removing Data Sharing Barriers; Expectations for the Healthcare Industry
    Session Chair: Riddhiman Das, TripleBlind
    - John Halamka, Mayo Clinic
    - David Albert, AliveCor Inc.
  • Next-Generation Data Sharing: Discoverable, Accessible, Interoperable Data (PANEL)
    Session Chair: John F. Kalafut, Asher Orion Group
    - Joel Sevinsky, Theiagen Genomics
    - Ittai Dayan, Rhino Health
    - Sharmila Majumdar, UCSF
    - Rajan Wadhwa, Anthem
  • Sustainable Data Systems via FAIR Data Principles
    Session Chair: Alex Sherman, MGH
  • Multi-Factor Data Science to Inform Clinical Research
    Session Chair: Charlotte Nelson, MATE Bioservices
    - Gundolf Schenk, UCSF
  • Translational AI: Innovation to Clinical Implementation and Reimbursement (PANEL)
    Session Chair: John J. Sninsky, Translational Consultant
    - Katy Wack, PathAI
    - Steve Anderson, LabCorp
    - Nigam Shah, Stanford
  • Leveraging Multiomic Data to Advance Rare Disease Drug Discovery and Development (PANEL)
    Session Chair: Justin Bingham, CENTOGENE
    - Purvesh Khatri, Stanford
    - Michael Hund, EB Research Partnership
  • AI/ML in Hospitals and Clinics / Digital Health Transformation / Predicting Clinical Outcomes
    Session Chair: Robert Hauser, Vidence
    - Alan Kaplan, LLNL
    - Peter Yu, Hartford Healthcare
    - Amir Bahmani, Stanford
  • Data Sciences for Proteogenomics and Targeted Therapies of Cancers
    - Gil Omenn, University of Michigan
  • PMWC 2022 Showcase
    - Kelly Hall, InheRET, Inc.
    - Calum Macrae, Harvard
`

 Session Chair Profile

M.D., Chief Health Information Officer and VP, Genetic and Genomic Services, UCSF Health

Biography
Dr Cucina is Vice President, Genetic and Genomic Services, and Chief Health Information Officer, for the UCSF Health system. Working with the Chief Genomics Officer, he is responsible for the strategy and operations of UCSF’s clinical genetic and genomics laboratories and services, and for the analytics, software, and information infrastructure to further the missions of UCSF Health. Dr. Cucina is board certified in Clinical Informatics and Internal Medicine, and practices in Hospital Medicine at UCSF’s Parnassus Campus.


 Session Chair Profile

Ph.D., Professor and Vice Chair, UCSF

Biography
Sharmila Majumdar, Ph.D., obtained her Ph.D. degree from Yale University in Engineering and Applied Sciences. After a short stay at Yale she joined UCSF as an Assistant Professor in 1989. Her research on machine and deep learning has a focus on imaging; prior work has focused on imaging technology development and translational, development of image processing, computer vision has been focused in the areas of osteoporosis, osteoarthritis, and lower back pain. She is the Executive and Scientific Director of the Center for Intelligent Imaging at UCSF. She was selected as a fellow of the American Institute of Medical and Biological Engineers in 2004, a fellow of the International Society of Magnetic Resonance in Medicine (ISMRM) in 2008, and awarded the ISMRM Gold medal in 2016. She is an active participant in the PMWC meetings. Her work over the last three decades has been extensively supported by the NIH and industry.


 Session Chair Profile

Ph.D., CSO, MATE Bioservices

Biography
Charlotte Nelson received her PhD from the University of California, San Francisco in Biological and Medical Informatics under the mentorship of Dr. Sergio Baranzini and Dr. Atul Butte. Here she envisioned the use of SPOKE, a heterogeneous knowledge graph, not solely as a graph for users to go from one node to another, but as a stage for biomedical innovation. This vision saw her embed the data from millions of patients onto SPOKE. Her research has showcased multiple clinical and pharmaceutical applications of SPOKE enhanced with real world data. Additionally, in collaboration with NASA, she showed that SPOKE’s capabilities could be expanded to basic science (non-medical) research to gain multi-domain insights of input datasets. In 2021, Mate Bioservices was launched, in partnership with UCSF, to harness the power of SPOKE with platforms and services to advance academic, clinical, and pharmaceutical research.

Talk
Beyond Data: A Knowledge Platform for Biomedical Research
Today’s most pressing biomedical problems will only be solved through multidisciplinary exchanges of data and knowledge. Mate Bioservices’ human-centric platforms and services leverage our powerful knowledge graph to enable this interchange. Now academic, pharmaceutical, and clinical researchers can accelerate innovation by investigating their private data through a multidisciplinary and multi-omics lens.


 Session Chair Profile

Ph.D., Independent consultant in Translational Science & Medicine

Biography
John is a biotechnology Translational Science & Medicine consultant with a comprehensive and deep understanding of the development and application of pioneering molecular procedures to the translation of research-grade biomarker assays into clinical-grade clinically adopted diagnostic tests. John oversaw the translation of an early stage research Next Generation sequencing test to a US government reimbursed and now widely adopted Laboratory Developed CLIA-CAP test for transplanted kidney rejection. He advises commercial translation efforts at Stanford University (SPARK) and University of California in San Francisco (CATALYST).


 Session Chair Profile

M.B.A., Senior Vice President Business Development, CENTOGENE GmbH

Biography
Justin Bingham joined CENTOGENE in 2017 and leads the Company’s business development and commercialization activities across pharma and biotech. Justin is a seasoned business executive with a track record of executing high value and successful partnerships within the healthcare sector. He brings vast experience in the commercialization of cutting-edge technologies that utilize high powered genomic sequencing. Prior to his role at CENTOGENE, Justin led business development activities for Synthetic Genomics, Inc. (SGI) across several industries, including vaccines, pharma, and life sciences. Additionally, Justin has held research positions at the Genomics Institute of the Novartis Research Foundation (GNF) and the exploratory biology research group at Pfizer, Inc. Justin completed his undergraduate work in Molecular Biology at the University of California, Santa Cruz, and holds an MBA from the Rady School of Business at the University of California, San Diego.


 Session Chair Profile

Ph.D., PHARM.D., Co-Founder & Chief Business Development Officer, Vidence

Biography
Rob is the Co-Founder and Chief Business Development & Analytics Officer for Vidence. His responsibilities include identifying business opportunities to leverage a growing volume of deep longitudinal clinical-genomic data for use in multiple healthcare channels including biopharmaceutical, provider and payer markets

Talk
Using AI/ML to Identify Patients at Risk for Missing Therapy
We will discuss a project implemented during the COVID-19 pandemic using AI/ML to identify patients at risk for not returning for therapy. The process of communications with the clinical staff and the results of the program.


 Session Chair Profile

Director, Center for Innovation and Bioinformatics, Mass General Hospital; Principal Associate in Neurology, Harvard Medical School

Biography
The focus of my work and research is conception, design, development of technology, platforms, infrastructure, and methods for collaborative clinical research and optimization of clinical research in disease-specific networks. We introduced such innovative concepts as NeuroBANK®, a patient-centric platform and accelerated research environment, utilized by hundreds of investigators at 80+ clinical sites in 14 countries; PRO-ACT™, a harmonized anonymized dataset from 23 ALS clinical trials utilized for future clinical trials’ design and AI and ML modeling; and The SigNET™ Platform for unique and secure patient identification across research continuum. All three platforms have won the Best Practice Award (2013-2015-2018-2020) from Bio-IT World Congress in Precision and Translational Medicine category, as “outstanding example of how technology innovations and strategic initiatives can be powerful forces for change in the life sciences.” Other research: technologies for secure collaboration, integration, harmonization, and sharing of clinical and research information by all clinical research enterprise participants.

Talk
Data FAIRness for Precision Research
Research data are invaluable resource of disease-specific knowledge. FAIRnization of data makes possible for academia, foundations, and industry to create pre-competitive resources for applying AI/ML modeling in identification of disease biomarkers, patient subpopulations, and creating disease progression and disease staging models, i.e., precision research and knowledge stratification.


 Session Chair Profile

CEO, TripleBlind

Biography
Riddhiman Das is CEO of TripleBlind. Das has spent most of his career in leadership roles in software and product development in startups, academia, and consulting across industries, including cybersecurity, fintech, digital identity, mobile payments, wireless systems, chipsets, healthcare, biometrics, security, and govtech. Previously, Das worked in corporate VC and M&A for Ant Financial, within the Alibaba Group. As head of international technology investments, Das focused on deals in enabling technologies for Alipay worldwide including blockchain, AI, security, IoT and computing. Das came to Ant Financial through EyeVerify’s successful exit. At EyeVerify, he helped develop a software-only, biometric method for verifying the identity of mobile users using the unique vein patterns in the whites of a person’s eyes. Das holds a bachelor’s degree and master’s degree in Computer Science and Electrical Engineering from the University of Missouri – Kansas City. He received the 2013 White House Champions of Change from President Barack Obama.


 Speaker Profile

Ph.D., CEO, Theiagen Genomics

Biography
Dr. Sevinsky has leveraged over two decades of experience in systems biology and taken aim at transforming public health and infectious disease surveillance through innovative implementation of NGS and bioinformatics technologies. During a three year tenure at the Colorado Department of Public Health and Environment, he led several initiatives to build NGS testing and bioinformatics capacity at the state, regional and national levels. In 2019 Dr. Sevinsky’s ambitions to impact public health exceeded his role as a government scientist, resulting in the formation of Theiagen Genomics. Dr. Sevinsky and his team now work with over four dozen public health laboratories nationally, and more than a dozen internationally in Africa and Asia. Prior to his time in public health, Dr. Sevinsky held several positions in non-profit and industry, working in applied technologies for diverse applications such as biomarker identification and biofuel/biochemical production.


 Speaker Profile

Ph.D., Principal Data Scientist, UCSF

Biography
Gundolf graduated from the Universities of Hamburg and Goettingen, Germany, in structural bioinformatics and machine learning. He continued theoretical and experimental methods development and data analyses for biomolecular research at the European Molecular Biology Laboratory and at Stanford University. At UCSF, he leads the technical integration and automatic detection of structure within various modalities of patient-centered data, including clinical notes and genomics.

Talk
UCSF InformationCommons: Multifactor Data Science to Advance Precision Medicine


 Speaker Profile

Ph.D., Vice President, Clinical Development and Regulatory Affairs, PathAI

Biography
Katy has been leading clinical and regulatory at PathAI for the last two years. One of her main focuses has been the NASH program, where she works to develop and qualify PathAI's unique drug development tools to advance NASH therapeutics with a consortium of close industry and academic partners. Katy has over a decade of clinical research and regulatory experience in digital pathology, diagnostics, and drug development, as well as an extensive background in liver research in tissue engineering, liver regeneration, and toxicology. Since 1998, Katy has been focused on harnessing quantitative imaging to unlock the intricate structure/function relationship in pathology, with the help of close, interdisciplinary collaborations.


 Speaker Profile

Ph.D., Chief Scientific Officer, Covance, Sr VP, LabCorp

Biography
Dr Anderson has been with the LabCorp organization for 26 years and has held a variety of positions including director of operations for ViroMed Laboratories, director of operations for Monogram Biosciences, director of operations for the Center for Molecular Biology and Pathology, director of operations for Integrated Oncology and Genetics, national director of Research and Development, and global head of LabCorp Clinical Trials. Dr Anderson is a member of a variety of professional societies including the American Association for Cancer Research, the American Society of Clinical Oncology and the Association for Molecular Pathology. Dr Anderson’s research interests are in the development and applications for molecular diagnostics, including several examples of companion diagnostics and pharmacogenomics assays. He has authored more than 175 articles and abstracts published in such journals as Genetics, Proceedings of the National Academy of Sciences, Clinical Chemistry, the Journal of Infectious Disease, Human Pathology, American Journal of Obstetrics and Gynecology, Oncogene, the Journal of the National Cancer Institute, Clinical Cancer Research, Breast Cancer Research, BMC Cancer, the Journal of Molecular Diagnostics, Archives of Pathology and Laboratory Investigation and Expert Reviews in Molecular Diagnostics.


 Speaker Profile

M.D., Ph.D., Professor of Medicine, Stanford University; Chief Data Scientist, Stanford Health Care

Biography
Dr. Nigam Shah is Professor of Medicine (Biomedical Informatics) at Stanford University, and serves as the Associate CIO for Data Science for Stanford Health Care. Dr. Shah's research focuses on bringing machine learning to clinical use safely, ethically and cost-effectively. Dr. Shah was elected into the American College of Medical Informatics (ACMI) in 2015 and was inducted into the American Society for Clinical Investigation (ASCI) in 2016. He holds an MBBS from Baroda Medical College, India, a PhD from Penn State University and completed postdoctoral training at Stanford University.


 Speaker Profile

Ph.D., Associate Professor, Stanford University

Biography
Research focuses on developing novel methods for leveraging heterogeneity present across independent cohorts to better understand human immune system for developing novel diagnostics and therapies for inflammatory diseases


 Speaker Profile

Ph.D., Research Scientist, Lawrence Livermore National Laboratory

Biography
Dr. Kaplan’s research centers around developing data-driven methods for problems in several application areas. He currently leads efforts developing advanced machine learning (ML) methods for healthcare and precision medicine applications. The focus of this work is on probabilistic approaches for noisy, heterogeneous, and irregularly sampled data streams, which present difficulties for many existing ML methods. One area is in traumatic brain injury (TBI), which has a large and diverse outcome space, in addition to arbitrary missingness patterns in clinical data points. The developed probabilistic methods allow for the analysis of patient subgroups and likelihood estimation over a large number of outcomes. Research in imaging involves the development of representation learning methods for brain MRI using a novel artificial neural network architecture. This approach compresses volumetric images and partitions the brain into regions that correspond across subjects in a purely data-driven approach.

Talk
Unsupervised Learning Approaches Using Messy Data for Precision Medicine
Unsupervised probabilistic models can be used to capture the underlying structure of data despite messy characteristics such as missingness. We use the models for traumatic brain injury data which consist of detailed records of clinical, blood biomarker, imaging, and comprehensive multidimensional outcome data.


 Speaker Profile

M.D., CEO and Cofounder, Buoy Health

Biography
Since founding Buoy out of Harvard Innovation Labs in 2014, Andrew has led the company through two successful funding rounds, raising over $67 million, with prominent healthcare investors including Optum, Cigna, Humana, WR Hambrecht + Co., and F-Prime. Recently, Andrew was named by Modern Healthcare as a Top 25 Emerging Leader, by Business Insider as one of 30 healthcare leaders under 40 to watch, a Digital Innovator by Employee Benefits News, one of Boston Business Journal's Top 40 Under 40 leaders, and recognized as a TEDMED Hive Innovator. Andrew holds a doctorate of medicine from Harvard Medical School and graduated magna cum laude from Harvard College.

Talk
Digital Health Transformation - Consumerism in Healthcare


 Speaker Profile

M.D., FACP, FASCO, Physician in Chief, Hartford HealthCare Cancer Institute, Hartford HealthCare

Biography
Dr. Peter Yu's expertise lies in the intersection of medical informatics, healthcare operations and public policy. While President of the American Society of Clinical Oncology, ASCO launched CancerLinq, which aggregates medical oncology data across U.S. academic and community practices, and 2 journals; JCO Global Oncology and JCO Cancer Clinical Informatics (Associate Editor). In his position as Clinical Member, Memorial Sloan Kettering Cancer Center he is on the leadership team for the strategic partnership between MSK and Hartford HealthCare whose mission is to accelerate the dissemination of knowledge from academic medical centers to community healthcare systems. Hartford HealthCare is a 7-hospital system caring for 1/3 of the Connecticut population. Dr. Yu serves on Hutchinson Institute for Cancer Outcomes Research (HICOR) Fred Hutchinson Cancer Research Center External Advisory Board, California Cancer Registry Advisory Committee, Epic Systems Adult Oncology Steering Board, and the American Joint Committee on Cancer (AJCC) Implementation Committee.

Talk
Improving Health and Economic Outcomes with AI
Structured data in the EHRs of 2806 patients who received a total of 17,513 chemotherapy treatments was aggregated and de-identified to develop a predictive algorithm for risk of chemotherapy induced febrile neutropenia. Linear, tree-based or ensemble methods were developed and a model to optimize clinical and financial outcomes using only 20 clinical features was identified.


 Speaker Profile

CEO, InheRET, Inc

Biography
Leading the strategic direction of INHERET, Kelly brings over 20 years as a cancer center administrator and 10 years in business development bringing genetics programs to health systems


 Speaker Profile

Ph.D., Stanford Lecturer and Director of Stanford Deep Data Research Computing Center, Stanford University

Biography
Dr. Amir Bahmani is the Director of Stanford Deep Data Research Computing Center. He has been working on large-scale distributed and parallel computing applications since 2008. He is an active researcher in the VA Million Veteran Program (MVP), Human Tumor Atlas Network (HTAN), the Human BioMolecular Atlas Program (HuBMAP), Stanford Metabolic Health Center (MHC), Stanford Integrated Personal Omics Profiling (iPOP) and Stanford Healthcare Innovation Lab. As a computer scientist, he is passionate about bridging the gap between computer scientists and biologists/physicians. He successfully launched Stanford University’s first Cloud Computing for Healthcare course, offered to students in Biology, Computer Science, Genetics, and Biomedical Data Science departments. His research draws on computationally intensive medical applications, cloud computing, data privacy in medical applications, database management systems, and pervasive and ubiquitous computing.

Talk
Deep Data in Precision Medicine
This talk provides a short set of examples for how to handle large-scale medical studies in a secure and scalable fashion. It assesses contemporary realities, identifies potentially promising research directions, and investigates the potential impact on the field of bioinformatics from a Computer Science perspective.


 Speaker Profile

M.B.A., CEO, EB Research Partnership

Biography
Michael is the CEO of EB Research Partnership, an innovative medical research organization dedicated to curing the life-threatening genetic skin disease Epidermolysis Bullosa (EB) and leading the way for rare diseases with a pioneering venture investing and technology business model. Michael previously served as the Director of Development for the Multiple Myeloma Research Foundation leading their successful $100 million Curing Cancer Now campaign. Previously, Michael spent over a decade in leadership at the actor and philanthropist Paul Newman’s Hole in the Wall Gang Fund, working on behalf of children and their families battling cancer and other life-threatening illness. Michael received his MBA from Yale University, CORe credential from Harvard Business School, and an undergraduate degree in Philosophy from the University of Kansas.


 Speaker Profile

M.D., Founder & Chief Medical Officer, AliveCor Inc.

Biography
Started Corazonix in 1985. Sold to Arrhythmia Research Technology in 1991. Started Data Critical in 1995. Went public in 1999 (DCCA: NASDAQ). Sold to GE Healthcare in 2001. Worked at GE Healthcare on New Technologies and Products. Left GE as Chief Clinical Scientist of GE Cardiology in 2004. Started InnovAlarm in 2004. InnovAlarm will be split into three separate startups. Lifetone introduced our first product, the LIfetone HL Fire Alarm and Clock as the first UL-listed, patented low frequency and tactile fire alarm in the guise of a standard alarm clock. Started AliveCor in 2010 to commercialize my smartphone ECG invention as one of the earliest and most clinically validated digital health innovations. 60 issued US patents, 25 currently pending. 100 published abstracts and journal articles in the Cardiovascular Literature. Specialties: Cardiovascular diagnostic devices (ECG, echo, CT, MRI, nuclear) Audio digital signal processing (alarms, Doppler Echo).

Talk
Removing Data Sharing Barriers; Expectations for the Healthcare Industry
This session brings together two sides of the data sharing innovation landscape – technologists and traditional healthcare systems. The group will discuss the breadth and depth of the impact data sharing technologies will have for insurers, digital health companies, and traditional healthcare systems seeking to innovate and push precision medicine forward.


 Speaker Profile

M.D., Ph.D., Professor of Medicine, Harvard Medical School and Co-Founder, Atman Health

Biography
Calum MacRae is a physician and scientist who works on disease mechanisms, translational genomic medicine and digital innovation. He is the PI of the AHA/Verily/AstraZeneca/Quest Diagnostics funded One Brave Idea program and the Apple Heart & Movement Study, as well as an Associate Member of the Broad Institute of Harvard and MIT and a Principal Faculty Member in the Harvard Stem Cell Institute. He was previously Chief of Cardiovascular Medicine at Brigham and Women's Hospital.

Talk
Systematizing Chronic Care
Data ingestion in medicine is typically a series of incompletely linked episodes. Systematizing all care transactions at an individual patient level offers the potential to create the data streams necessary to optimize chronic disease management, stratify individual risk in novel ways and reimagine clinical workflows.


 Speaker Profile

Eng, M.B.A., Senior Leader, Enterprise Data & Analytics, Anthem Digital

Biography
Rajan Wadhwa is a senior leader in the Enterprise Data & Analytics group in Anthem Digital. He is accountable for Analytics in the Cost of Care, Clinical, Whole Person Profile as well as Product space. He is also responsible for Clinical Rules Engine, an application that creates Clinical intelligence used in Care Management, Disease Management and Patient Safety applications across Anthem. Rajan brings a broad and deep experience in Data and Analytics with over 22 years of experience. In his previous roles, he led Data and Analytics for Sales and Marketing group in a Financial Services company, led large Data and Analytics technology implementation in High Tech, Automotive, Real Estate and Telecom industries.


 Speaker Profile

M.D., Ph.D., Director; Center for Computational Medicine & Bioinformatics, University of Michigan

Biography
Gil Omenn is an expert in genetics, proteomics, bioinformatics, and precision medicine. He is Distinguished University Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics, and Public Health, and Director of the University-wide Center for Computational Medicine & Bioinformatics at the University of Michigan. He is a former Howard Hughes Medical Institute Investigator, a longtime NCI-funded PI, a physician long involved in Genetic Counseling at the University of Washington and University of Michigan, and the first CEO of the University of Michigan Health System. His current work in proteogenomics is focused on alternative splice variants as a new class of potential protein cancer biomarkers. He is the elected Chair of the global Human Proteome Project. More broadly, he serves on the elected Council of the National Academy of Medicine; was president and board chair of the American Association for the Advancement of Science (AAAS); chaired the Presidential/Congressional Commission on Risk Assessment and Risk Management during 1994-1997 and the Institute of Medicine 2012 report on “Evolution of Translational Omics: Lessons Learned and Path Forward”; co-chaired the i2b2 tranSMART Foundation; and has served on the boards of Amgen Inc, Rohm & Haas Company, Esperion Therapeutics, Galectin Therapeutics, and Oncofusion. He has been involved in the Personalized Medicine World Conferences for several years.